Press releases

25 Nov 2014

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

read more
09 Oct 2014

Synthon Announces Filing of Glatiramer Acetate 40 mg/mL ANDA Containing a Paragraph IV Certification

read more
06 May 2014

Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

read more
15 Apr 2014

Synthon obtains European approvals for sevelamer

read more
02 Apr 2014

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC

read more
27 Mar 2014

Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate

read more
14 Jan 2014

Synthon Biopharmaceuticals ramping up for initiation of Phase I study with its frontrunner ADC SYD985

read more
12 Mar 2013

Leica Biosystems and Synthon Biopharmaceuticals partner to develop a companion diagnostic program for targeted cancer therapies

read more
22 Jan 2013

Synthon Biopharmaceuticals reports positive early results with its second generation HER2-antibody-drug conjugate

read more
18 Jul 2012

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

read more